In this supplement to EMJ Hematology, two leading haematologists, Prof Adriano Venditti and Prof Lars Bullinger, discussed the management of patients with acute myeloid leukaemia (AML) and fms-related tyrosine kinase 3 (FLT3) gene mutations. Specifically, the roles for emerging treatment options and maintenance strategies in improving outcomes for patients with a FLT3 internal tandem duplication (ITD) mutation were explored.
EMJ Hematology 9 [Supplement 3] . 2021
June 2021
In this issue
Latest articles
All articles![](https://www.emjreviews.com/wp-content/uploads/2024/07/Filgrastim-Prophylaxis-for-Neutropenia-in-Myelodysplasia-Pre-Surgery-Case-Report-Web-940x564.jpg)
![](https://www.emjreviews.com/wp-content/uploads/2024/07/Diffuse-Large-B-Cell-Lymphoma-of-Spleen-A-Key-Differential-of-Nodular-Splenomegaly-940x564.jpg)
![](https://www.emjreviews.com/wp-content/uploads/2024/07/The-Impact-of-‘Pre-conception-on-Conception-An-Inadvertent-Form-of-Infertility-Web-940x564.jpg)
![](https://www.emjreviews.com/wp-content/uploads/2024/07/Hema_Article_Waheed-940x564.jpg)